Because gastric emptying is slowed, food lingers longer in the stomach, creating that heavy, unsettled feeling
New to GLP-1 medications Sensitive to nausea or GI side effects Goal is maintenance, not aggressive loss Biohacker or metabolic optimization focus Prefer a slower, more sustainable protocol The standard titration schedule used in clinical settings
Generation I Semaglutide GLP-1 only Peak Weight Loss 14.9% STEP 1 trial 68 weeks Receptor Coverage Single GLP-1 FDA Status Approved (Wegovy, 2021) FIRST PUBLISHED Wilding et al., NEJM 2021 Generation II Tirzepatide GLP-1 + GIP Peak Weight Loss 22.5% SURMOUNT-1 trial 72 weeks Receptor Coverage Dual GLP-1, GIP FDA Status Approved (Zepbound, 2023) First Published Jastreboff et al., NEJM 2022 Generation III Retatrutide GLP-1 + GIP + GCGR Peak Weight Loss 24.2% Phase 2 48 weeks (highest dose) Receptor Coverage Triple GLP-1, GIP, GCGR FDA Status Phase 3 (TRIUMPH program) First Published Jastreboff et al., NEJM 2023 -SELECTED LITERATURE Key Retatrutide research and clinical publications
Even among the reputable telehealth providers that are riding the peptide wave, the selection is usually limited to GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro
At Cymbiotika, we believe that wellness begins with trust and transparency, and we are committed to providing our community with high-quality, science-backed supplements
Should not be consumed by pregnant or lactating women and children below 18 years old
